- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
Suven Life Sciences' Board approved Q1 financial results. Consolidated net loss was ₹127.61 Cr, with total income at ₹11.09 Cr. Clinical trials advanced with 95% enrollment for SUVN-502 Phase 3 and SUVN-G3031 Phase 3 initiated. Proceeds from preferential warrants continue to be received.